In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Strong Market For Regenerative Medicine Deals Drives Value

Untapped market opportunities for treating and possibly curing underserved diseases have spurred an active deal-making environment in regenerative medicine, according to a new report from Datamonitor Healthcare.

Regenerative Medicine Deals Market Intelligence
Advertisement

Latest From Market Intelligence

Deals Shaping the Medical Industry, August 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced July 2017.

Deals BioPharmaceutical

In Vivo's Deals Of The Month, July 2017

In Vivo's editors pick July's most significant deals, including AZ and Merck's oncology deal, and late-stage funding for Silk Road Medical. (Free article.)

BioPharmaceutical Deals

In Vivo's Deals Of The Month, June 2017

In Vivo's editors pick June's most significant deals, including Idorsia's IPO and Medtronic's outcomes-based contract with Aetna. (Free article.)

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Podcast: Big Pharma Licensing Trends

Big pharma comprises a smaller proportion of the deals market than mid-size and smaller biopharmas or biotechs, but it is the biggest spender. A free audio/video excerpt on big pharma licensing trends from Datamonitor Healthcare's webinar, "From R&D Investment To Externalization: Where Is The Pharma Industry Maximizing Value?"

Deals Market Intelligence

Deals In Depth: May 2017

AstraZeneca could pay up to $2.1 billion in an Anticalin protein therapeutics deal with Pieris, centered around respiratory diseases. In the latest CRO takeover, Thermo Fisher Scientific bought Patheon for $7.2 billion. Biopharma financing declined in May compared with April, mostly due to a decrease in public offering value.

BioPharmaceutical Medical Device
See All
UsernamePublicRestriction

Register